Myrexis, Inc. (MYRX)

[surf1944]

7:01AM Myriad Pharma presents key findings from its cancer metabolism inhibitor, MPC-9528; reports MPC-9528 is a potent and selective inhibitor (MYRX) 3.82 : Co announces evidence demonstrates that treatment with MPC-9528 results in significant tumor growth inhibition and that the co-administration of niacin improves the therapeutic index of MPC-9528. Additionally, a large panel of tumor cell lines and primary human tumor tissue indicate that approximately 40% of all cancers may carry a biochemical defect making them respond well to the combination of niacin and MPC-9528 treatment.